EGFR Mutation Targeting Molecular Probe for PET Imaging
Launched by PEKING UNIVERSITY CANCER HOSPITAL & INSTITUTE · Oct 11, 2024
Trial Information
Current as of August 20, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on developing a special imaging tool, called a molecular probe, that helps doctors detect a specific type of cancer mutation known as the EGFR mutation. This mutation can affect treatment options for patients with lung cancer, particularly those who might benefit from targeted therapies called TKIs. The goal is to see how well this new imaging tool can identify lung cancer patients with an EGFR Del 19 mutation, which is important for determining the best treatment approach.
To participate in this study, you need to be between 18 and 75 years old and have a confirmed diagnosis of lung cancer with measurable disease. You should also be able to understand and sign the consent form, and have a life expectancy of more than three months. However, people with severe liver or kidney issues, pregnant or nursing individuals, and those who have certain other health conditions may not be eligible. If you join the trial, you can expect to undergo imaging tests, which are non-invasive procedures that will help the researchers see if the new tool is effective. This trial is currently not yet recruiting participants, but it aims to provide valuable information that could improve lung cancer care in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Male and female, aged 18-75 years old (including 18 and 75 years old), ECOG score 0 or 1.
- • 2. Patients could understand and sign the informed consent form voluntarily with good compliance.
- • 3. Patients with histologically or cytologically or clinically confirmed lung cancer with measurable disease.
- • 4. Women had to be using an effective contraceptive method (effective contraceptive means sterilisation, intrauterine hormonal devices, condoms, contraceptives/pills, sexual abstinence, or partner's removal of the vas deferens) during the study and for 6 months after the study. Men should consent to subjects who must use contraception during the study period and for 6 months after the end of the study period.
- • 5. Predicted survival greater than 3 months;
- Exclusion Criteria:
- • 1. Severe hepatic or renal dysfunction;
- • 2. Pregnant or nursing;
- • 3. Known allergy to the investigational drug or its excipients in study;
- • 4. Unable to comply with the PET/CT imaging procedures;
- • 5. Claustrophobia or other psychiatric disorders;
- • 6. Other conditions deemed unsuitable for participation in the trial;
About Peking University Cancer Hospital & Institute
Peking University Cancer Hospital & Institute is a leading research and treatment facility dedicated to advancing oncology through innovative clinical trials and comprehensive patient care. Renowned for its commitment to cancer research, the institution integrates cutting-edge scientific exploration with clinical practice to enhance treatment outcomes and improve quality of life for cancer patients. With a multidisciplinary team of experts, Peking University Cancer Hospital & Institute focuses on developing novel therapeutic strategies and diagnostic tools, contributing significantly to the global fight against cancer. Its collaborative approach fosters partnerships with academic institutions and industry leaders, facilitating the translation of research findings into effective clinical applications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported